Hannu Ryöppönen

• Healthcare Professionals
•  
• Patients
•  
• Investors
•  
• Media
•  
• R&D
•  
• Jobs
•  
• Sustainability
•  
• About us
•  

• Novo Nordisk in brief
• Novo Nordisk way of management
• Management
  • Board of Directors
  • Executive Management
• Corporate governance
• Global offices
• Changing diabetes
• Changing possibilities in haemophilia
• Download centre
• Contact us

• 
• Print

Board of Directors

Hannu Ryöppönen, Member of the board

Mr Ryöppönen is a member of the Board of Directors of Neste Oil Oyj, Amer Sports Oyj and Rautaruukki Oyj, all in Finland. Mr Ryöppönen is the Chairman of the Audit Committees of Amer Sports Oyj and Rautaruukki Oyj, and a member of the Audit Committee of Neste Oil Oyj.

Until 1 April 2009 Mr. Ryöppönen served as deputy CEO in Stora Enso Oyj. Mr Ryöppönen joined Stora Enso Oyj as CFO in 2005 and in 2007 he was also appointed deputy CEO.

Mr Ryöppönen joined Royal Ahold in the Netherlands as member of the Executive Board and CFO in 2003. During his tenure at Ahold until 2005 he served on the Board of Directors of the ICA Group, Sweden, in¬cluding the chairmanship of the Audit Committee. From 1999 to 2003, Mr Ryöppönen was Finance Direc¬tor of the private equity firm Industri Kapital Group based in London, UK. Mr Ryöppönen served as execu¬tive vice president and CFO of the IKEA Group based in Humlebæk, Denmark, from 1985 to 1998. He was deputy CEO of IKANO Asset Management from 1998 to 1999. From 1977 to 1985, Mr Ryöp¬pönen held various management positions at Chemical Bank in the US and the UK, as well as for Alfa Laval in the US and Sweden.

Mr Ryöppönen is chairman of the Board of Directors of three Altor private equity funds, Altor 2003 GP Limited, Altor Fund II GP Limited and Altor III GP Limited, Jersey, Channel Islands and a member of the Board of Directors of the private equity fund Value Creation Investments Limited, Jersey, Channel Islands.

Mr Ryöppönen has a BA in Business Administration (1976) from Hanken School of Economics, Helsinki.

Mr Ryöppönen was elected to the Board of Directors of Novo Nordisk A/S at the Annual General Meeting in March 2009 for the first time.

In March 2009, the Board of Directors of Novo Nordisk A/S elected Mr Ryöppönen as member of the Audit Committee and designated him as financial expert under both Danish and US law.

In January 2009, the Board of Directors of Novo Nordisk A/S assessed that Mr Ryöppönen is regarded as an independent board member as defined in Section V.4 of Recommendations for corporate governance designated by the NASDAQ OMX Copenhagen (2008). At the same time, the Board of Directors also assessed that the special competences possessed by Mr Ryöppönen that are important for the performance of his duties are his international executive background and thorough understanding of managing finance operations in global organisations, in particular in relation to accounting, financing and capital markets issues, but also his experience within private equity and Mergers & Acquisitions (M&A).

Mr Ryöppönen is a Finnish national, born on 25 March 1952.

Back to top